Search

Your search keyword '"Brown, Stav"' showing total 182 results
Start Over Author "Brown, Stav"
182 results on '"Brown, Stav"'

8. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).

Author

Brown, Stav, Tadros, Audree B., Montagna, Giacomo, Bell, Tajah, Crowley, Fionnuala, Gallagher, Emily J., and Dayan, Joseph H.

Subjects
GLUCAGON-like peptide-1 receptor, AXILLARY lymph node dissection, GLUCAGON-like peptide-1 agonists, LOGISTIC regression analysis, BODY mass index
Abstract

Purpose: Patients undergoing axillary lymph node dissection (ALND) for breast cancer face a high risk of lymphedema, further increased by high body mass index (BMI) and insulin resistance. GLP-1 receptor agonists (GLP-1RAs) have the potential to reduce these risk factors, but their role in lymphedema has never been investigated. The purpose of this study was to determine if GLP-RAs can reduce the risk of lymphedema in patients undergoing ALND. Methods: All patients who underwent ALND at a tertiary cancer center between 2010 and 2023 were reviewed. Patients with less than 2 years of follow-up from the time of ALND were excluded. Race, BMI, radiation, chemotherapy history, pre-existing diagnosis of diabetes, lymphedema development after ALND, and the use of GLP-1RAs were analyzed. Multivariate logistic regression analysis was performed to assess if there was a significant reduction in the risk of developing lymphedema after ALND. A sub-group analysis of non-diabetic patients was also performed. Results: 3,830 patients who underwent ALND were included, 76 of which were treated with. GLP-1 RAs. The incidence of lymphedema in the GLP-1 RA cohort was 6.6% (5 patients). Compared to 28.5% (1,071 patients) in the non-GLP-1 RA cohort. On multivariate regression analysis, patients who were treated with GLP-1 RA were 86% less likely to develop lymphedema compared to the non-GLP-1 RA cohort (OR 0.14, 95% CI 0.04-0.32, p < 0.0001). A BMI of 25 kg/m 2 or greater was a statistically significant risk factor for developing lymphedema with an odds ratio of 1.34 (95% CI 1.16-1.56, p < 0.0001). Diabetes was associated with lymphedema development that closely approached statistical significance (OR 1.32, 95% CI 0.97-1.78, p = 0.06). A subgroup analysis solely on non-diabetic patients showed similar results. The odds of developing lymphedema were 84% lower for patients without diabetes treated with GLP1-RAs compared to those who did not receive GLP-1 RAs (OR 0.16, 95% CI 0.05-0.40, p < 0.0001). Conclusion: GLP1-RAs appear to significantly reduce the risk of lymphedema in patientsundergoing ALND. The mechanism of action may be multifactorial and not limited to weight reduction and insulin resistance. Future prospective analysis is warranted to clarify the role of GLP-1RAs in reducing lymphedema risk. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report.

Author

Crowley, Fionnuala, Brown, Stav, Gallagher, Emily J., and Dayan, Joseph H.

Subjects
GLUCAGON-like peptide 1, GLUCAGON-like peptide-1 agonists, LYMPHEDEMA, PATIENT reported outcome measures, ADJUVANT chemotherapy
Abstract

Introduction: Lymphedema is a major public health issue for many women undergoing breast cancer treatment. Although weight loss has been reported to be beneficial in the treatment of lymphedema, no studies to date have examined the use of GLP-1RAs for the treatment of secondary lymphedema. This case report describes a patient who experienced significant resolution of her breast cancer-related lymphedema after initiation of a GLP-1RA for weight loss. Main symptoms and/or important clinical findings: Nine months postoperatively the patient developed arm swelling and disability. While on adjuvant chemo and hormonal therapy, her weight increased dramatically and peaked 4 years later. Corresponding to her weight gain was significant worsening of her symptoms. The main diagnoses, therapeutic interventions, and outcomes: Due to adjuvant cancer-related weight gain and inability to lose weight with diet and exercise, she was referred for evaluation and diagnosed with lymphedema. The patient started treatment with a Glucagon-like peptide 1 receptor agonist and lost 24% of her body weight over the next 13 months. The improvement in her lymphedema mirrored her weight loss. Her limb volume difference dropped from 10.3% down to 3.4% and she no longer required a compression garment. Her imaging demonstrated return of lymphatic pumping and she experienced a significant improvement in quality of life, assessed by a validated lymphedema-specific patient reported outcome (PROM). She remains on hormonal therapy, no longer needs compression and is back to regular exercise without impairment. Conclusions: GLP-1 RAs provide a potential medical option for many patients struggling with weight gain and lymphedema. We have observed by all objective measures a significant reduction in lymphedema and the elimination of compression in the case presented as a direct result of GLP-1 RA. This may also reduce a patient's BMI to the point where they become a good candidate for lymphovenous bypass or vascularized lymph node transplant when indicated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Dysregulation of Lymphatic Endothelial VEGFR3 Signaling in Disease.

Author

Kuonqui, Kevin, Campbell, Adana-Christine, Sarker, Ananta, Roberts, Arielle, Pollack, Bracha L., Park, Hyeung Ju, Shin, Jinyeon, Brown, Stav, Mehrara, Babak J., and Kataru, Raghu P.

Subjects
MOLECULAR pathology, VASCULAR endothelial growth factors, GRAFT rejection, PROTEIN-tyrosine kinases, PATHOLOGY
Abstract

Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR3), a receptor tyrosine kinase encoded by the FLT4 gene, plays a significant role in the morphogenesis and maintenance of lymphatic vessels. Under both normal and pathologic conditions, VEGF-C and VEGF-D bind VEGFR3 on the surface of lymphatic endothelial cells (LECs) and induce lymphatic proliferation, migration, and survival by activating intracellular PI3K-Akt and MAPK-ERK signaling pathways. Impaired lymphatic function and VEGFR3 signaling has been linked with a myriad of commonly encountered clinical conditions. This review provides a brief overview of intracellular VEGFR3 signaling in LECs and explores examples of dysregulated VEGFR3 signaling in various disease states, including (1) lymphedema, (2) tumor growth and metastasis, (3) obesity and metabolic syndrome, (4) organ transplant rejection, and (5) autoimmune disorders. A more complete understanding of the molecular mechanisms underlying the lymphatic pathology of each disease will allow for the development of novel strategies to treat these chronic and often debilitating illnesses. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Doxycycline for the treatment of breast cancer-related lymphedema

Author

Brown, Stav, Dayan, Joseph H., Coriddi, Michelle, McGrath, Leslie, Kataru, Raghu P., and Mehrara, Babak J.

Subjects
Pharmacology, Pharmacology (medical)
Abstract

Purpose: Secondary lymphedema is a common complication of cancer treatment for which no effective drug treatments yet exist. Level I clinical data suggests that doxycycline is effective for treating filariasis-induced lymphedema, in which it decreases tissue edema and skin abnormalities; however, this treatment has not been tested for cancer-related lymphedema. Over the past year, we used doxycycline in an off-label manner in patients with breast cancer-related secondary lymphedema. The purpose of this report was to retrospectively analyze the efficacy of this treatment.Methods: Patients who presented to our lymphedema clinic between January 2021 and January 2022 were evaluated, and barring allergies or contraindications to doxycycline treatment, were counseled on the off-label use of this treatment. Patients who wished to proceed were treated with doxycycline (200 mg given orally once daily) for 6 weeks. After IRB approval of this study, lymphedema outcomes were retrospectively reviewed.Results: Seventeen patients with a mean follow-up of 17.0 ± 13.2 weeks were identified in our retrospective review. Although doxycycline treatment had no significant effect on relative limb volume change or L-Dex scores, we found a significant improvement in patient-reported quality of life. Analysis of patient responses to the Lymphedema Life Impact Scale showed a significant improvement in the total impairment score due to improvements in the physical and psychological well-being subscales (p = 0.03, p = 0.03, p = 0.04, respectively).Conclusion: This small, retrospective study did not show significant improvements in limb volume or L-Dex scores in patients with breast cancer-related lymphedema treated with doxycycline. However, our patients reported improvements in quality-of-life measures using a validated lymphedema patient-reported outcome instrument. Our results suggest that doxycycline may be of use in patients with breast cancer-related lymphedema; however, larger and more rigorous studies are needed.

Published
2022

48. Spotlight in Plastic Surgery: April 2022

Author

Phillips, Brett T., primary, Barreras-Espinoza, Jorge A., additional, Bergmeister, Konstantin D., additional, Brown, Stav, additional, Bustos, Samyd S., additional, Facio, Jose A., additional, Gallo, Lucas, additional, Kantar, Rami S., additional, Klifto, Kevin M., additional, Luan, Anna, additional, Onyejekwe, George O., additional, and Gosain, Arun K., additional

Published
2022
Full Text
View/download PDF

50. Pharmacological Treatment of Secondary Lymphedema

Author

Brown, Stav, primary, Dayan, Joseph H., additional, Coriddi, Michelle, additional, Campbell, Adana, additional, Kuonqui, Kevin, additional, Shin, Jinyeon, additional, Park, Hyeung Ju, additional, Mehrara, Babak J., additional, and Kataru, Raghu P., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results